AU2023297939A1 - Novel lipid nanoparticle compositions and uses thereof - Google Patents

Novel lipid nanoparticle compositions and uses thereof Download PDF

Info

Publication number
AU2023297939A1
AU2023297939A1 AU2023297939A AU2023297939A AU2023297939A1 AU 2023297939 A1 AU2023297939 A1 AU 2023297939A1 AU 2023297939 A AU2023297939 A AU 2023297939A AU 2023297939 A AU2023297939 A AU 2023297939A AU 2023297939 A1 AU2023297939 A1 AU 2023297939A1
Authority
AU
Australia
Prior art keywords
lipid
cells
composition
ganglioside
dissolved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023297939A
Other languages
English (en)
Inventor
Heliang SONG
Victoria Trantow
Bin Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytodigm Inc
Original Assignee
Cytodigm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytodigm Inc filed Critical Cytodigm Inc
Publication of AU2023297939A1 publication Critical patent/AU2023297939A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2023297939A 2022-06-29 2023-06-29 Novel lipid nanoparticle compositions and uses thereof Pending AU2023297939A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263356557P 2022-06-29 2022-06-29
US63/356,557 2022-06-29
PCT/US2023/026541 WO2024006414A1 (en) 2022-06-29 2023-06-29 Have been novel lipid nanoparticle compositions and uses thereof

Publications (1)

Publication Number Publication Date
AU2023297939A1 true AU2023297939A1 (en) 2024-11-28

Family

ID=89381439

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023297939A Pending AU2023297939A1 (en) 2022-06-29 2023-06-29 Novel lipid nanoparticle compositions and uses thereof

Country Status (6)

Country Link
US (2) US12303569B2 (enExample)
EP (1) EP4547224A4 (enExample)
JP (1) JP2025525308A (enExample)
CN (1) CN119403544A (enExample)
AU (1) AU2023297939A1 (enExample)
WO (1) WO2024006414A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120948302A (zh) * 2024-05-13 2025-11-14 国立医药品食品卫生研究所 使用离心场流分级检测颗粒的方法
WO2025250539A1 (en) * 2024-05-29 2025-12-04 Cytodigm, Inc. Pharmaceutical composition comprising sialic acid for treating diseases related to the lung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150291969A1 (en) * 2014-01-30 2015-10-15 Chromatin, Inc. Compositions for reduced lignin content in sorghum and improving cell wall digestibility, and methods of making the same
CN114245807B (zh) * 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
US12582612B2 (en) * 2020-10-05 2026-03-24 Cytodigm, Inc. Pharmaceutical composition of Siglec-binding agents

Also Published As

Publication number Publication date
US12303569B2 (en) 2025-05-20
EP4547224A4 (en) 2026-08-19
EP4547224A1 (en) 2025-05-07
US20250001003A1 (en) 2025-01-02
JP2025525308A (ja) 2025-08-05
WO2024006414A8 (en) 2025-02-27
US20250099394A1 (en) 2025-03-27
WO2024006414A1 (en) 2024-01-04
CN119403544A (zh) 2025-02-07

Similar Documents

Publication Publication Date Title
JP6442551B2 (ja) 薬物送達用の脂質ナノ粒子の生成方法
EP3695850B1 (en) Pharmaceutical compositions comprising a negatively charged drug and a cationic lipid
US12303569B2 (en) Lipid nanoparticle compositions and uses thereof
JP4951338B2 (ja) 脂質に封入された干渉ｒｎａ
KR101164256B1 (ko) 폴리에틸렌글리콜 개질된 지질 화합물 및 그의 용도
AU2009330859B2 (en) Pharmaceutical composition containing an anionic drug, and a production method therefor
KR101948839B1 (ko) 음이온성 약물 함유 약제학적 조성물 및 그 제조방법
EP3842412A1 (en) Biodegradable compound, lipid particles, composition containing lipid particles, and kit
ES2386549T3 (es) Composición para inhibir la expresión de un gen diana
CN1981044A (zh) 包封干扰rna的脂质
CN117534585B (zh) 一种可电离阳离子脂质化合物及其制备方法与应用
US20260000627A1 (en) Novel lipid nanoparticle compositions and uses thereof
WO2024121167A1 (en) Compounds and compositions for delivery of agents to cells
US20120244210A1 (en) Composition for suppressing expression of target gene
US20140039034A1 (en) Composition for suppressing expression of target gene
WO2026036007A1 (en) Novel lipid nanoparticle compositions and uses thereof for treating diseases in bone marrow
EP4563142A1 (en) Lipid nanoparticle and pharmaceutical composition
US20120207818A1 (en) Composition for suppressing expression of target gene
WO2025063214A1 (ja) 核酸を内封したリガンド修飾脂質ナノ粒子の製造方法

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ NOVEL LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ WU, BIN; SONG, HELIANG AND TRANTOW, VICTORIA